Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Atezolizumab Coverage & Prior Auth Update |…
    Ask Trek AI about this page
    ModifiedAnthemPolicy CC-0128

    Atezolizumab (Tecentriq, Tecentriq Hybreza) coverage criteria

    Customize your policy alerts

    Sign up for Anthem Policy CC-0128 alerts

    Get alerted when Policy CC-0128 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical prior authorization and coverage criteria for Tecentriq (atezolizumab) and Tecentriq Hybreza across multiple oncology indications, specifying clinical scenarios, combinations, and restrictions for Anthem members.

    Policy Summary
    PayerAnthem
    PolicyAtezolizumab (Tecentriq, Tecentriq Hybreza) coverage criteria
    Policy CodePolicy CC-0128
    Change TypeMaterial revisions (step therapy addednew indications and coding updates)
    Effective DateJun 1, 2026
    Last ReviewDec 8, 2025
    Next Review DateDec 8, 2025
    Key ActionObtain prior authorization and document indication-specific clinical criteria and recommended molecular testing prior to initiating therapy.
    SourceLink
    POLICY UPDATE CHANGES

    Add Tecentriq Hybreza step therapy and new step therapy table.

    Remove age criteria for alveolar soft part sarcoma (ASPS) and update wording/formatting.

    Add FDA indication for combination use with Zepzelca (lurbinectedin) in extensive-stage small cell lung cancer.

    Modified non-squamous NSCLC criteria to allow use in actionable molecular markers and PD-L1 expression and allowed subsequent line or maintenance therapy.

    Removed requirement for platinum therapy and ECOG in certain NSCLC updates and added cervical cancer criteria.

    Added new indication for alveolar soft part sarcoma and later clarified do not approve criteria.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=12FDA / NCCN indications and recommended uses listed
    Step therapy addedTecentriq Hybreza step therapy requirement present
    PreferredPreferred on Commercial & Medicare lists
    3 triggersSituations where therapy may not be approved
    ICD-10+ICD-10 additions

    Coverage Criteria and Approval Rules

    Summary of revised coverage groups

    Coverage criteria were revised across several tumor types; specifics appear in other sections of the policy not included in this part. Summaries of major changes are below.

    NSCLC updates: Non‑squamous NSCLC criteria modified to allow use based on actionable molecular markers and PD‑L1 expression; allowed for subsequent line or maintenance therapy; platinum requirement removed in some contexts

    See full criteria in main policy (document history entries 05/17/2024; 05/21/2021; 12/09/2019)

    Alveolar soft part sarcoma: Indication added and broadened to all stages (age criteria removed)

    Added 12/12/2022; clarified 11/17/2023; see history 05/17/2024

    Urothelial carcinoma: Use as subsequent treatment following platinum therapy removed per FDA withdrawal; related indications updated

    Refer to 05/21/2021 document history and main policy text

    Hepatocellular carcinoma: Child‑Pugh score language and HCC-related wording updated

    Select review 02/23/2024

    Tecentriq (atezolizumab) or Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) may not be approved when any of the following apply: the individual has documented disease progression while receiving another PD-1 or PD-L1 inhibitor; the individual is currently receiving therapy for an autoimmune disease or other chronic condition that requires treatment with a systemic immunosuppressant; or the request does not meet the applicable indication-specific criteria outlined elsewhere in this policy.

    Several indication-specific changes were made to the policy following regulatory and guideline updates. Notable revisions include allowing non-squamous NSCLC use guided by actionable molecular markers and PD-L1 expression, expanding NSCLC to permit subsequent-line or maintenance therapy, adding mesothelioma criteria, and clarifying or adding explicit 'do not approve' criteria. Additionally, certain indications were removed or altered in response to prior FDA withdrawals (see urothelial-related changes). These documented changes are reflected in the policy history and coding updates.

    Requests that do not meet the specific, indication-related clinical criteria described in this policy are considered not medically necessary. Approval decisions require the submitted clinical information to match the applicable coverage criteria for the requested diagnosis and regimen.

    Use of Tecentriq as subsequent treatment following platinum therapy for urothelial carcinoma was removed from coverage per the FDA withdrawal and policy updates; such requests are considered not medically necessary under the current policy and will be denied when submitted for that indication.

    Regimens and Combination Therapies

    RegimenIndication / Key criteriaCoverage status
    Atezolizumab in combination with nab-paclitaxel (albumin-bound paclitaxel) and carboplatinFirst-line treatment of recurrent, advanced, or metastatic nonsquamous NSCLC; individual does not have presence of actionable molecular markersCovered when criteria met
    RegimenIndication / Key criteriaCoverage status
    Atezolizumab in combination with carboplatin, paclitaxel, and bevacizumab (or bevacizumab biosimilar)First-line, subsequent-line, or maintenance treatment of recurrent, advanced, or metastatic NSCLC; used as combination regimen per label/NCCNCovered when criteria met
    RegimenIndication / Key criteriaCoverage status
    Atezolizumab with etoposide and carboplatin followed by maintenance atezolizumab monotherapyFirst-line treatment of extensive-stage small cell lung cancer (ES-SCLC); induction with etoposide + carboplatin followed by maintenance atezolizumabCovered when criteria met
    Atezolizumab in combination with Zepzelca (lurbinectedin)First-line treatment option for ES-SCLC per label/NCCN (combination with lurbinectedin)Covered when criteria met
    RegimenIndication / Key criteriaCoverage status
    Atezolizumab in combination with bevacizumab (or biosimilar)First-line treatment of advanced, unresectable, or metastatic hepatocellular carcinoma (HCC); also adjuvant HCC at high risk of recurrence when used with bevacizumabCovered when criteria met
    RegimenIndication / Key criteriaCoverage status
    Atezolizumab in combination with carboplatin plus nab-paclitaxelNSCLC combination regimens as described in IMpower studies; applicable for first-line or subsequent contexts per policy nodesCovered when criteria met
    Atezolizumab with other chemotherapy per IMpower studiesUse in NSCLC combinations supported by IMpower clinical trial references (see policy references)Covered when criteria met
    RegimenIndication / Key criteriaCoverage status
    Atezolizumab plus nab-paclitaxel (albumin-bound paclitaxel)Treatment of PD-L1 selected advanced triple-negative breast cancer per referenced trials (clinical trial evidence cited: Adams et al., Emens et al.)Covered when criteria met

    Line of Therapy Criteria

    First-line

    First‑line uses covered when ALL of the following indication‑specific conditions are met, as listed below.

    HCC first‑line: Individual has advanced, unresectable, or metastatic hepatocellular carcinoma AND is using atezolizumab in combination with bevacizumab (or bevacizumab biosimilar)

    Chunk 9.A; overview chunk 2

    NSCLC nab‑paclitaxel first‑line: Individual has recurrent, advanced, or metastatic nonsquamous NSCLC AND is using atezolizumab in combination with nab‑paclitaxel (albumin‑bound paclitaxel) and carboplatin; AND individual does not have presence of actionable molecular markers

    Chunk 9.C; historical addition chunk 20

    ES‑SCLC first‑line: Individual has extensive‑stage small cell lung cancer AND is using atezolizumab in combination with etoposide and carboplatin (followed by maintenance atezolizumab monotherapy) OR in combination with lurbinectedin (Zepzelca)

    Chunk 10.J; overview chunk 2

    Biomarkers and Testing Requirements

    inv-30: PD-L1 (TC) — TC ≥ 1%
    ThresholdPD-L1 tumor cell expression (TC) ≥ 1%
    ContextRequired for adjuvant treatment of stage IB–IIIB NSCLC after prior adjuvant therapy
    Source guidanceReferenced in NSCLC criteria (NCCN 2A) within policy
    inv-31: BRAF V600 — (BRAF V600 testing reference)
    Test requiredBRAF V600 mutation testing required for melanoma combination therapy with cobimetinib and vemurafenib
    ContextUsed to determine eligibility for atezolizumab plus targeted BRAF/MEK therapy in unresectable or metastatic melanoma

    Billing and Diagnosis Codes

    HCPCSHCPCS
    J9022Injection, atezolizumab, 10 mg [Tecentriq]
    J9024Injection, atezolizumab, 5 mg and hyaluronidase-tqjs [Tecentriq Hybreza]
    HCPCS (duplicate listing confirmation)HCPCS
    J9022Injection, atezolizumab, 10 mg [Tecentriq]
    J9024Injection, atezolizumab, 5 mg and hyaluronidase-tqjs [Tecentriq Hybreza]
    ICD-10 DiagnosisICD-10
    C22.0Liver cell carcinoma
    C22.8Malignant neoplasm of liver, primary, unspecified as to type
    C22.9Malignant neoplasm of liver, not specified as primary or secondary
    C33Malignant neoplasm of trachea
    C34.00-C34.92Malignant neoplasm of bronchus and lung
    C43.0-C43.9Malignant melanoma of skin
    C45.0-C45.9Mesothelioma
    C49.0-C49.9Malignant neoplasm of other connective and soft tissue
    C53.0-C53.9Malignant neoplasm of cervix uteri
    Z85.118Personal history of other malignant neoplasm of bronchus and lung
    Covered ICD-10-CM additions (examples)ICD-10
    C45.0-C45.9ICD-10-CM codes added for mesothelioma (per coding review)
    Covered ICD-10-CM additionsICD-10
    C53.0-C53.9ICD-10-CM codes for cervical cancer added
    Historic ICD-10-CM additionsICD-10
    C68.0-C68.9ICD-10-CM codes added previously (urothelial related codes)
    ICD-10-CM additions (HCC)ICD-10
    C22.0-C22.9ICD-10-CM codes for hepatocellular carcinoma added
    inv-13: PD-L1 tumor cell expression — TC ≥ 1%
    ThresholdPD-L1 tumor cell expression (TC) ≥ 1%
    Applicable settingRequired for treatment of stage IB–IIIB NSCLC after prior adjuvant therapy
    Document referenceSpecified in NSCLC criteria node H (Chunk 10) of the policy
    inv-14: ECOG performance status — ECOG references were removed for extensive SCLC per NCCN guidance
    ChangeECOG requirement removed for extensive-stage SCLC per NCCN guidance
    ECOG definition

    Provider Actions, Authorization, and Denial Risks

    Prior Authorization

    Medical necessity — meet indication‑specific criteria

    Prior authorization may be approved when the patient meets any of the listed indication-specific clinical criteria (examples include first-line HCC in combination with bevacizumab, adjuvant high‑risk HCC with bevacizumab, specified first-line and subsequent NSCLC regimens, ES‑SCLC combinations, melanoma with BRAF V600 combination therapy, ASPS monotherapy, cervical cancer combinations, and mesothelioma subsequent therapy).

    • Approval logic: Requests for Tecentriq or Tecentriq Hybreza may be approved if any of the indication-specific criteria in the COVERAGE CRITERIA are met (see chunks 8–11).
    • Examples of covered scenarios are enumerated in chunk 9 (HCC, NSCLC, ES‑SCLC, etc.) and chunk 11 (mesothelioma).
    Prior Authorization

    Prior authorization implied; benefit tiering lists Tecentriq as preferred

    Prior authorization is implied for medical benefit coverage and, effective 06/01/2026, Tecentriq is listed as the preferred agent and Tecentriq Hybreza as non‑preferred on the Commercial and Medicare medical benefit lists.

    Definitions and Reference Terms

    inv-24: Actionable molecular markers (EGFR, ALK, ROS1, BRAF, NTRK, MET, RET) — testing recommended prior to therapy; if unavailable, treat as absent
    ActionTest for EGFR, ALK, ROS1, BRAF, NTRK, MET, RET prior to initiating therapy
    If insufficient tissuePerform repeat biopsy and/or plasma testing where feasible
    If testing unavailableTreat patient as though driver oncogenes are absent
    inv-25: ECOG Performance Status — Scale 0-5 describing patient's functional status used to assess suitability for therapy
    DefinitionECOG Performance Status: Scale 0–5 describing patient's functional status
    Example scores0 = fully active; 1 = restricted in strenuous activity but ambulatory; 2 = ambulatory and capable of self-care but unable to work; 3 = limited self-care; 4 = completely disabled; 5 = dead

    Background

    Atezolizumab is an anti–PD-L1 immune checkpoint inhibitor indicated for multiple tumor types. It is used as monotherapy and in combination regimens across indications including non‑small cell lung cancer, extensive‑stage small cell lung cancer, hepatocellular carcinoma (commonly in combination with bevacizumab), unresectable or metastatic melanoma in BRAF V600–mutant disease (in combination with targeted agents), alveolar soft part sarcoma, cervical cancer, and mesothelioma. NCCN guidance and trial evidence (referenced in the policy) inform specific regimen selection, biomarker testing requirements, and line‑of‑therapy considerations.

    Policy Summary
    PayerAnthem
    PolicyAtezolizumab (Tecentriq, Tecentriq Hybreza) coverage criteria
    Policy CodePolicy CC-0128
    Change TypeMaterial revisions (step therapy addednew indications and coding updates)
    Effective DateJun 1, 2026
    Last ReviewDec 8, 2025
    Next Review DateDec 8, 2025
    Key ActionObtain prior authorization and document indication-specific clinical criteria and recommended molecular testing prior to initiating therapy.
    SourceLink
    On This Page
    Coverage Criteria and Approval RulesRegimens and Combination TherapiesLine of Therapy CriteriaBiomarkers and Testing RequirementsBilling and Diagnosis CodesProvider Actions, Authorization, and Denial RisksDefinitions and Reference TermsBackground

    Second-line

    Subsequent‑line (second‑line) coverage is met when ALL of the following are satisfied for the NSCLC subsequent‑use pathway:

    NSCLC subsequent therapy after platinum or targeted agents: Individual has recurrent, advanced, or metastatic NSCLC (nonsquamous or squamous) AND disease has progressed during or following platinum‑containing chemotherapy OR progressed during or following treatment with a targeted agent for the expressed oncogene (e.g., EGFR, ALK, ROS1, BRAF, NTRK, MET); AND when progression after targeted agent, individual is using in combination with carboplatin and nab‑paclitaxel

    Chunk 9.F and Chunk 10.G

    First-line | Second-line | Maintenance

    First‑line, second‑line, and maintenance contexts updated to allow overlap of uses in NSCLC and other tumor types; apply the indication‑specific nodes above.

    ref
    Related markers
    BRAF is listed among actionable molecular markers (EGFR, ALK, ROS1, BRAF, NTRK, MET, RET)
    inv-32: Actionable molecular markers (EGFR, ALK, ROS1, BRAF, NTRK, MET, RET)
    Markers listedEGFR, ALK, ROS1, BRAF, NTRK, MET, RET
    Testing recommendationNCCN panel recommends testing prior to initiating therapy to guide treatment selection
    If testing not feasibleIf insufficient tissue, repeat biopsy and/or plasma testing should be done; if still unavailable, treat as though driver oncogenes are absent
    inv-33: PD-L1 — (PD-L1 references across indications)
    Multiple indications referencePD-L1 is used across NSCLC indications to guide use (e.g., first-line, subsequent, maintenance) and was added to NSCLC criteria updates
    Policy change noteNon-squamous NSCLC modified to allow use based on PD-L1 expression per document history
    Guideline sourceNCCN recommendations inform PD-L1 use in policy (see referenced NCCN guidance)
    inv-34: Actionable molecular markers (examples: MET, others)
    Examples of markersMET (example provided in NSCLC subsequent therapy updates)
    Broader groupOther actionable markers include EGFR, ALK, ROS1, BRAF, NTRK, RET
    Policy usePresence/absence of these markers informs eligibility for specific NSCLC regimens (e.g., nab-paclitaxel+carboplatin requires absence of actionable markers)
    ECOG Performance Status scale 0–5 describes patient's functional status used to assess suitability for therapy
    Policy historyDocument history notes removal of ECOG for ES-SCLC in 05/21/2021 and later updates
  1. Commercial Medical Benefit listing: Preferred Agents = Tecentriq; Non‑Preferred Agents = Tecentriq Hybreza (effective 06/01/2026).
  2. Medicare Medical Benefit listing: Preferred Agents = Tecentriq; Non‑Preferred Agents = Tecentriq Hybreza (effective 06/01/2026).
  3. Step Therapy

    Tecentriq Hybreza step therapy — preferred agent(s) required

    Tecentriq Hybreza is subject to a step therapy requirement: even if clinical criteria are met, the benefit plan may require use of a preferred agent(s) first; Tecentriq Hybreza may be approved when the individual is unable to receive intravenous Tecentriq due to no venous access.

    • Benefit plans may require use of a preferred agent or agents when Tecentriq Hybreza is otherwise approvable (chunk 12).
    • Specific approval condition: Tecentriq Hybreza requests may be approved if the individual is unable to use intravenous Tecentriq due to no venous access (chunk 13).
    • A list of preferred products is referenced in the policy (chunk 13).
    Billing Rule

    Step edits / quantity limits — none specified here; previous quantity limits retired

    Quantity limits were retired (05/21/2021); the document does not specify step edits or ongoing quantity limits in this extract.

    • Document history notes removal/retirement of quantity limits on 05/21/2021 (chunk 20).
    • Current excerpt does not list explicit step edits or quantity limits (chunk 18).
    Documentation Required

    Required molecular marker testing and measures before therapy

    Actionable molecular marker testing (EGFR, ALK, ROS1, BRAF, NTRK, MET, RET) is recommended prior to initiating therapy; if insufficient tissue is available, repeat biopsy and/or plasma testing should be performed, and if not feasible patients may be treated as though driver oncogenes are absent.

    • Markers to test: EGFR, ALK, ROS1, BRAF, NTRK, MET, RET (chunk 4).
    • If testing not possible: repeat biopsy and/or plasma testing recommended; if infeasible, treat as though driver oncogenes are absent (chunk 4).
    • ECOG performance status definitions are provided for contextual use (chunk 4).
    Note

    Provide supporting clinical references (IMvigor210, IMpower trials, other citations)

    References and clinical trial citations that support indication and medical necessity determinations (for example IMvigor210, IMpower trials, and trial reports of atezolizumab combinations) should be available on request.

    • Examples of cited trials/publications include IMvigor210 and IMpower studies and specific trial reports listed in the References section (chunk 21).
    • Providers should have these references available to support medical necessity decisions upon request (chunk 21).
    Denial Risk

    Denial triggers — prior PD‑1/PD‑L1 progression or systemic immunosuppression

    Requests may be denied if the individual has disease progression on another PD‑1 or PD‑L1 inhibitor, or if the individual is receiving systemic immunosuppressive therapy for an autoimmune or chronic condition; requests that do not meet the listed criteria will also be denied.

    • Do not approve if disease progression occurred with another PD‑1 or PD‑L1 inhibitor (chunk 11).
    • Do not approve if receiving systemic immunosuppressant therapy for autoimmune or chronic conditions (chunk 11).
    • Requests not meeting the indication‑specific criteria are considered not medically necessary and may be denied (chunk 11).
    Denial Risk

    Denial triggers — inconsistent with 'do not approve' or removed indications

    Requests inconsistent with updated 'do not approve' criteria or for indications removed following FDA actions (for example removal of subsequent‑line urothelial indications following withdrawal) may be denied.

    • Document history documents removal of urothelial subsequent‑line use per FDA withdrawal and addition of 'do not approve' criteria (chunks 18 and 20).
    • Providers should confirm that the requested indication remains listed as approvable in the current policy before submission (chunk 18).
    Use in policyUsed to assess suitability for therapy; specific ECOG requirements vary by indication
    inv-26: NCCN — National Comprehensive Cancer Network guidelines referenced
    AcronymNCCN = National Comprehensive Cancer Network
    RoleNCCN clinical practice guidelines are referenced throughout the policy to define appropriate use and marker testing
    Document versionsPolicy cites multiple NCCN disease-specific guideline versions (e.g., NSCLC V3.2025, HCC V2.2024)